SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Dendreon Corp. today announced that Mitchell H. Gold, M.D., President and CEO, will discuss PROVENGE(R) (sipuleucel-T), the Company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer, during a focus session panel at the 8th Annual BIO CEO & Investor Conference in New York City at 9:00 a.m. ET on February 14, 2006.
The panel session entitled “Cancer Immunotherapies Coming of Age,” will address current approaches, progress and prospects for cancer immunotherapy, or cancer vaccines.
Dr. Gold will be joined on the panel by Alex McPherson, M.D., Ph.D., President and CEO, Biomira Inc.; Peter Working, Ph.D., Senior Vice President of Research and Development, Cell Genesys, Inc.; John P. Longenecker, Ph.D, President and CEO, Favrille Inc.; and Hyam Levitsky, M.D., Professor of Oncology, Johns Hopkins University School of Medicine. Mark Monane, M.D., Managing Director of Equity Research, Biotechnology and Life Sciences, Needham & Co., LLC, will serve as the panel’s moderator.
An audio webcast recording of the focus session can be accessed at www.dendreon.com or http://ceo.bio.org/opencms/ceo/2006/index.jsp approximately 12 hours after the presentation and will be archived for three months.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company uses its experience in antigen identification, antigen engineering and antigen-presenting cell processing to produce active immunotherapy product candidates to potentially stimulate a cell-mediated immune response. PROVENGE (sipuleucel-T) is Dendreon’s lead active cellular immunotherapy in Phase 3 development for prostate cancer. The Company also discovered Trp-p8, a cold receptor and transmembrane ion channel in pre- clinical development, which is over-expressed in breast, prostate, lung and colon cancers. For more information about the Company and its programs, visit www.dendreon.com.
Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of a clinical trial for PROVENGE will not support an application for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, including collaborators, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon’s business, financial condition and results of operations are contained in Dendreon’s public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
Dendreon Corporation
CONTACT: Monique M. Greer, Sr. Director, Corporate Communications ofDendreon Corporation, +1-206-829-1500
Web site: http://www.dendreon.com//
